Maternal-fetal rh blood group incompatibility immunosorbent therapy device

Abstract

The invention relates to a maternal-fetal Rh blood group incompatibility immune adsorption therapeutic instrument. The maternal-fetal Rh blood group incompatibility immune adsorption therapeutic instrument is characterized in that using Rhesus monkey red blood cells to replace human Rh positive O-shaped red blood cells, washing the Rhesus monkey red blood cells with normal saline at the temperature of 4 DEG C and 37 DEG C, using 25 mmol / L PB lysis buffer having the pH of 7.4 and 35 mmol / L PB lysis buffer having the pH of 7.4 to alternatively washing the Rhesus monkey red blood cells till the upper layer is colorless, fully dialyzing harmful hemoglobin in the Rhesus monkey red blood cells, preparing Rhesus monkey blood ghost cells containing D antigen, detecting the antigenicity and installing an adsorbing device made from a high biocompatibility material, allowing the blood ghost cells to form high density compressed cell absorbing agent via repeated high-speed centrifugation, arranging screens in an inlet and an outlet of the absorbing device so as to form a defensive line for preventing filtering out of cell l debris, wherein Rh antibodies are combined with the blood ghost cells to form a fixed compound after blood plasma is filtered, the red cell solute is stopped by the screens of the absorbing device, blood plasma without morbid substances is transfused back after filtered by the absorbing device so as to treat a haemolytic disease by clearing the Rh antibodies in the blood plasma.

Description

technical field [0001] The invention relates to an immunoadsorption therapeutic apparatus for maternal-fetal Rh incompatibility in the medical field, which is mainly used for removing anti-fetal red blood cell antibodies and erythrocyte lysates in plasma of pregnant women with maternal-fetal Rh blood incompatibility. Background technique [0002] The fetus inherits half of the genetic components of the father and half of the mother, and the fetal red blood cells can carry antigens from the father, showing that the blood type of the fetus is different from that of the mother. When the fetal red blood cells enter the mother's blood circulation, the mother's immune system is induced to produce antibodies, and the antibodies pass through the placenta and enter the fetal blood circulation system, combining with fetal red blood cells, causing fetal red blood cells to be destroyed, resulting in maternal-fetal blood group incompatibility hemolytic disease in fetuses and newborns . ...

AI Technical Summary

Problems solved by technology

However, plasma exchange can only remove part of the antibodies in the blood, and cannot stop the continuous production of antibodies, nor can it reverse the existing maternal-fetal blood group incompatibility hemolytic disease. It needs continuous plasma exchange to be effective. Pregnant women who had fetal hydrops two weeks ago, or whose spouses are homozygous for the pathogenic antigen, especially while removing part of the pathogenic antibody, also removed a large amount of plasma (multiple beneficial components), although the replacement fluid Supplementation has been made, but the removed plasma and its various beneficial components cannot be completely supplemented, and the replacement fluid for the replacement is large and expensive. Supplementing allogeneic plasma is prone to various side effects such as infectious diseases and infusion reactions, which limits plasma exchange. the general development of

Images